<p>Pituitary adenomas(PA) are typically benign, slow-growing neoplasms. About 60–65 percent of diagnosed PAs are hormone-secreting PAs, with the remaining 35–40 percent being NFPA (non-functional tumours) which don’t release hormones at the detectable levels. Recurrence following surgery has been reported to be as high as 12–47 percent, either as a consequence of new growth or growth from remaining tumor post partial resection. Crucially, partial resection as well as possibility of additional growth persist even after repeat surgery for the residual disease. Because adjuvant radiotherapy (RT) significantly lowers the likelihood of NFA recurrence, it has become a more appealing choice for treating identified residual tumors. 40 year old male patient had been referred to our Otolaryngology unit with complaints of blurring of vision and headache, insidious onset, gradually progressive, dull in nature since 2 months. Nervous system and ENT examinations were unremarkable. Computed Tomography brain revealed well defined heterodense lobulated mass lesion involving sella turcica extending into suprasellar cistern with anterior extension onto optic chiasma, laterally to cranial nerves and the internal carotids, and posterior into sella turcica. Patient had an similar history 7 years back, the diagnosis of pituitary macroadenoma was made and patient underwent endoscopic Transnasal Transsphenoidalexcision. macroadenoma. Postoperative RT was not advised to the patient. Patient under went Histopathological examination suggested Pituitary revision endoscopic Transnasal Transsphenoidalexcision. In most situations, it is preferable to consider early repeat surgery when it is feasible, with the goal of achieving the safest tumor removal for long-term vision protection in the nonfunctioning adenoma. To lower the risk of long-term hypopituitarism and lower radiation exposure, the goal is to maintain normal pituitary function as well as avoid radiotherapy wherever feasible.</p>